These statements have not been evaluated by the FDA and the compound is not intended to diagnose, treat, cure, or prevent any disease
In the future, with the in-depth exploration of the mechanism of GLP-1R action and the development of multi-target agonists (e.g., GLP-1R/GIPR dual agonists), GLP-1R-related therapeutics are expected to make breakthroughs in a wider range of disease areas (e.g., nonalcoholic steatohepatitis, AD, etc.), providing a more precise and highly effective strategy for the treatment of metabolic diseases and related complications
Heres a clear look at what the evidence says and how to make it work for you
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
An added advantage of GLP-1 medications is their potential to aid in weight loss